Wave Life Sciences Ltd. Ordinary Shares (WVE) Stock
Key stats
- Market cap
- $674.52M
- Price / Earnings ratio
- -3.2x
- EPS (TTM)
- -$1.06
- Volume
- Loading
- 52-week high
- $21.73
- 52-week low
- $3.04
Source: third-party data provider, as of November 13, 2026
Compare with WVE
Recent news

WAVE Life Sciences Q3 Earnings Call Highlights
WAVE Life Sciences Q3 Earnings Call Highlights
WVE

Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
WVE

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
WVE

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
WVE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 45.72
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.04
- SMA 50
- $3.80
- Price below SMA 50
- EMA 50
- $3.87
- Price below EMA 50
- SMA 200
- $7.02
- Price below SMA 200
- EMA 200
- $7.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.32 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

WAVE Life Sciences Q3 Earnings Call Highlights
WAVE Life Sciences Q3 Earnings Call Highlights
WVE

Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
WVE

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
WVE

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
WVE

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
WVE

WAVE Life Sciences Q2 Earnings Call Highlights
WAVE Life Sciences Q2 Earnings Call Highlights
WVE

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
WVE

Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
WVE

New Strong Buy Stocks for July 22nd
New Strong Buy Stocks for July 22nd
WVE

3 Promising Genomics Stocks to Add to Your Portfolio in 2026
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
WVE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Wave Life Sciences Ltd. Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul B. Bolno M.B.A., M.D. | President, CEO & Director | 1974 |
| Mr. Kyle B. Moran CFA | CFO & Principal Accounting Officer | 1971 |
| Dr. Gregory L. Verdine Ph.D. | Founder & Director | 1959 |
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer | 1961 |
| Dr. Christopher Francis Ph.D. | Senior VP of Corporate Development & Head of Emerging Areas | 1978 |
| Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer | — |
| Ms. Linda Rockett J.D. | Senior VP & General Counsel | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 45.72
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.04
- SMA 50
- $3.80
- Price below SMA 50
- EMA 50
- $3.87
- Price below EMA 50
- SMA 200
- $7.02
- Price below SMA 200
- EMA 200
- $7.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $22.40
- High
- $44.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.7 | -14.4 | ||||||||||
| 2022 | -32.6 | +4.7 | -16.3 | -3.9 | -24.7 | +153.9 | -20.1 | +24.3 | +22.8 | +35.3 | -11.9 | +60.9 |
| 2023 | -20.5 | -17.8 | +3.1 | -13.8 | +3.4 | -12.5 | +22.8 | -0.5 | +26.7 | -10.6 | +0.2 | -8.3 |
| 2024 | -19.1 | +20.2 | +20.3 | -21.9 | +9.0 | -20.0 | +26.1 | -6.8 | +47.7 | +65.2 | +9.2 | -19.0 |
| 2025 | -13.1 | -10.9 | -19.6 | -0.3 | -24.3 | +4.0 | +24.2 | +11.2 | -23.9 | +28.6 | -6.6 | +129.4 |
| 2026 | -18.9 | +3.7 | -47.7 | +3.4 | -10.1 | -7.2 | -5.7 | -14.6 | -25.6 | -7.5 | -2.8 |



